ROCKVILLE, Md., May 8, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced it will present at the Bank of America Merrill Lynch 2019 Healthcare Conference on Wednesday, May 15, 2019, at the Encore Wynn Hotel, Las Vegas, NV:
Fireside chat: Wednesday, May 15, 2019, at 10:40 a.m. PDT (1:40 p.m. EDT)
Gene Therapy Panel: Wednesday, May 15, 2019, at 4:20 p.m. PDT (7:20 p.m. EDT)
A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the fireside chat webcast will be available on the same website for approximately 30 days following the presentation.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
Heather Savelle, 212-600-1902
David Rosen, 212-600-1902
SOURCE REGENXBIO Inc.